George Y Wang

Array ( [id] => 18764044 [patent_doc_number] => 11814430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Increasing responses to checkpoint inhibitors by extracorporeal apheresis [patent_app_type] => utility [patent_app_number] => 17/175503 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12595 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559824 [patent_doc_number] => 11725059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Antibodies targeting B-cell maturation antigen and methods of use [patent_app_type] => utility [patent_app_number] => 17/173716 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 41537 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 900 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900819 [patent_doc_number] => 20210179735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => TRISPECIFIC BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/165760 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807933 [patent_doc_number] => 20210130486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/133413 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17133413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067338 [patent_doc_number] => 20210269553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2 [patent_app_type] => utility [patent_app_number] => 17/125601 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060149 [patent_doc_number] => 11104736 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Methods of treating cancer in subjects having dysregulated lymphatic systems [patent_app_type] => utility [patent_app_number] => 17/119207 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 14008 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778045 [patent_doc_number] => 20210115123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => TRISPECIFIC INHIBITORS FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/118974 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449361 [patent_doc_number] => 20230190637 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODY AND PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/095102 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449361 [patent_doc_number] => 20230190637 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODY AND PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/095102 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029757 [patent_doc_number] => 11091562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Engineered IGA antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/091890 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 59 [patent_no_of_words] => 81252 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701361 [patent_doc_number] => 11787860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Anti-CD47 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/949459 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 27187 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16794096 [patent_doc_number] => 20210123913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 [patent_app_type] => utility [patent_app_number] => 17/081366 [patent_app_country] => US [patent_app_date] => 2020-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17081366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18526365 [patent_doc_number] => 11713351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-01 [patent_title] => Immunotoxin for treating cancer [patent_app_type] => utility [patent_app_number] => 17/076409 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 27873 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598098 [patent_doc_number] => 20210024629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => BINDING MOLECULES SPECIFIC FOR ASCT2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/060711 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17060711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541045 [patent_doc_number] => 20200407458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ANTI CD30 CHIMERIC ANTIGEN RECEPTOR AND ITS USE [patent_app_type] => utility [patent_app_number] => 17/019709 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570686 [patent_doc_number] => 20210009692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors [patent_app_type] => utility [patent_app_number] => 17/018241 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17018241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991840 [patent_doc_number] => 20210230260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/015442 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105826 [patent_doc_number] => 11958907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => CD73 blockade [patent_app_type] => utility [patent_app_number] => 17/009817 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 32466 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17009817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657451 [patent_doc_number] => 20210054087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => THERAPEUTIC ANTIBODIES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/005073 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506215 [patent_doc_number] => 20200385471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES [patent_app_type] => utility [patent_app_number] => 16/997565 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997565 [rel_patent_id] =>[rel_patent_doc_number] =>)